Welcome to our dedicated page for Teladoc Health news (Ticker: TDOC), a resource for investors and traders seeking the latest updates and insights on Teladoc Health stock.
Teladoc Health reports news on its virtual care business, including financial results, segment performance, product innovation, technology investment, and governance updates. The company delivers and orchestrates care across patients, care providers, platforms, and partners through relationships with health plans, employers, providers, health systems, and consumers.
Recurring updates focus on Integrated Care, which includes virtual care solutions such as primary care, mental health, chronic care management, and telehealth enablement, and BetterHelp, the company’s direct-to-consumer online mental health offering. Company news also includes earnings calls, investor conference participation, board appointments and retirements, inducement equity awards, and strategic commentary on its clinical model and care-delivery platform.
Teladoc Health (NYSE: TDOC) said CEO Chuck Divita will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 3:45 p.m. PT (6:45 p.m. ET). A live audio webcast and replay will be available on the company's investor relations site.
Investors can listen live or view the replay at the investor events page: https://ir.teladochealth.com/news-and-events/events-and-presentations.
Teladoc Health (NYSE: TDOC) announced that CEO Chuck Divita will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025 at 12:30 p.m. ET.
A live audio webcast and replay will be available via the company’s investor events page at http://ir.teladochealth.com/news-and-events/events-and-presentations/. Contact for investors is Michael Minchak at IR@teladochealth.com or 617-444-9612.
TytoCare will integrate its FDA-cleared home diagnostic technology with Teladoc Health (NYSE: TDOC) to augment Primary360 and 24/7 Care programs. The integration will begin in 2026 with a phased rollout to select customers and enables remote clinical-grade exams (lungs, throat, ear, heart, skin, temperature) using TytoCare's handheld device and AI-powered Lung Sounds Suite.
Key facts: FDA clearance for the AI Lung Sounds Suite; respiratory conditions represent >40% of TytoCare diagnoses; AI trained on >7 million exams.
Teladoc Health (NYSE:TDOC) announced an employment inducement award effective November 1, 2025 for new Chief Technology Officer Dave Ross. The grant includes 86,906 restricted stock units (RSUs) and 86,906 performance stock units (PSUs) at target (up to 173,812 shares if maximum is earned).
The RSUs vest with one-third on the first anniversary and the remainder quarterly over the next two years. The PSUs are earned over a three-year performance period based on specified financial metrics. The award was approved by the Compensation Committee and granted under the Teladoc Health 2023 Employment Inducement Incentive Award Plan as permitted by NYSE Rule 303A.08.
Teladoc Health (NYSE: TDOC) reported Third Quarter 2025 results for the period ended September 30, 2025. Revenue was $626.4M, down 2% year‑over‑year; net loss was $49.5M, or $0.28 per share; and adjusted EBITDA was $69.9M, down 16% year‑over‑year. Integrated Care revenue rose 2% to $389.5M with a 17.0% adjusted EBITDA margin; BetterHelp revenue fell 8% to $236.9M with a 1.6% adjusted EBITDA margin. Third Quarter results included a $12.6M goodwill impairment and $17.0M stock‑based compensation. Full‑year 2025 guidance: revenue $2,510–2,539M; adjusted EBITDA $270–287M; FCF $170–185M.
Teladoc Health (NYSE: TDOC) announced a CFO transition and provided preliminary third-quarter 2025 financial results on October 23, 2025. Mala Murthy will step down as CFO and remain in the role through November 21, 2025; an interim finance structure will report to CEO Chuck Divita while a search is conducted.
The company reaffirmed its full-year 2025 consolidated revenue and adjusted EBITDA outlook and reported preliminary unaudited Q3 2025 results: consolidated revenue $626.4 million and consolidated adjusted EBITDA $69.9 million. A conference call to discuss Q3 results is scheduled for October 29, 2025 at 5:00 p.m. ET.
Teladoc Health (NYSE: TDOC) will release third quarter 2025 financial results on Wednesday, October 29, 2025 after the market close.
The company will host a conference call to review results at 5:00 p.m. ET the same day. U.S. participants can dial 1-833-470-1428 and use access code 609817. International dial-in numbers are available via the global numbers page. A live audio webcast will be available at the investor events page, and a replay will be posted there for on-demand listening for approximately 90 days.
Teladoc Health (NYSE: TDOC) launched a new workplace safety capability within its AI-enabled Clarity monitoring solution to help hospitals and health systems detect and intervene in escalating incidents.
The capability uses video and audio cues to analyze facial expressions, threatening gestures, and aggressive language, providing intelligent notifications to care teams for early intervention. Teladoc cited workforce safety data including that more than 80% of nurses have experienced workplace violence and that healthcare workers are five times more likely to face workplace violence than other industries; a report estimates workplace and community violence costs hospitals more than $18 billion annually.
The solution will be implemented with select hospitals and health systems in Q1 2026 as part of Teladoc's partner development program.
Teladoc Health (NYSE:TDOC) reported mixed Q2 2025 results with revenue declining 2% year-over-year to $631.9 million. The company posted a net loss of $32.7 million ($0.19 per share), significantly improved from the $837.7 million loss in Q2 2024. Adjusted EBITDA decreased 23% to $69.3 million.
The Integrated Care segment showed growth with revenue up 4% to $391.5 million, while BetterHelp segment revenue declined 9% to $240.4 million. The company secured a new $300 million revolving credit facility and paid $550.6 million to retire convertible senior notes. For full-year 2025, Teladoc expects revenue between $2.501-$2.548 billion and projects continued challenges in the BetterHelp segment with revenue declining 6.8-9.2%.
Wingspan has secured $24 million in Series B funding led by Touring Capital, bringing its total funding to $54 million. The company, which provides contractor management and payroll solutions, has demonstrated significant growth with a 200% expansion in customer base, 5x increase in average ACV, and has processed over $3 billion in payments.
The company announced Wingspan Embed, a new solution enabling HR platforms to manage contractors with features including tax automation, instant payouts, and insurance. Teladoc Health (NYSE: TDOC), a key client, uses Wingspan to manage payments for 10,000 healthcare providers, saving 28 hours monthly on payment processing.
The funding will accelerate Wingspan Embed's adoption and expand the company's presence in healthcare, insurance, staffing, and professional services sectors.